SOURCE: Intellipharmaceutics International Inc

Intellipharmaceutics International Inc

April 05, 2011 12:00 ET

Intellipharmaceutics International Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference

NEW YORK, NY--(Marketwire - April 5, 2011) - Taglich Brothers, Inc. is pleased to announce that Dr. Isa Odidi, CEO & Founder and Shameze Rampertab, VP Finance & CFO of Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: I) will be presenting at our 8th Annual Small Cap Equity Conference May 3rd, 2011. The Conference will take place at the New York Athletic Club, New York City. To request additional information or to register, contact Taglich Brothers at 212-779-2971 or visit www.taglich.com.

About Taglich Brothers

Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

About Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: I) is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a unique and validated multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, pain and infection. To date, Intellipharmaceutics has disclosed four products that are awaiting FDA approval.

Contact Information

  • Contact:
    Taglich Brothers
    Karen Payne
    212-779-2971